“For the tens of millions of Americans who endure the pain and disabling effects of migraine disease, we congratulate Amgen and Novartis on the FDA approval of erenumab. This new class of medicine is the first to be developed and approved for the prevention of migraine attacks. We now call on all stakeholders in healthcare to work together to ensure that people with migraine disease have access to CGRP inhibitor medicines. For a community that has suffered pain, neglect, disability and stigma for so many years, today is the hopeful start of a new era in treating migraine disease.”
-Kevin Lenaburg, Executive Director
CHAMP (Coalition For Headache And Migraine Patients)

Posted in